Canada markets closed

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
166.95+5.10 (+3.15%)
At close: 04:00PM EDT
166.90 -0.05 (-0.03%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close161.85
Open159.82
Bid154.41 x 800
Ask180.00 x 800
Day's Range158.48 - 169.04
52 Week Range118.18 - 426.56
Volume225,093
Avg. Volume283,461
Market Cap17.242B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?

    BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • Motley Fool

    Why Shares of BeiGene Popped Today

    BeiGene's (NASDAQ: BGNE) shares were up by more than 13% on Tuesday at 2:50 p.m. ET thanks to a regulatory body in China accepting one of the company's supplemental biologics licensing application filings for a new indication for its drug tislelizumab. The Center for Drug Evaluation (CDE) will now evaluate whether tislelizumab is sufficiently safe and effective to treat metastatic gastric junction adenocarcinoma in conjunction with chemotherapy for patients whose tumors express the PD-1 biomarker, potentially giving BeiGene the green light for an expansion of its commercialization in China. If regulators ultimately opt to approve the company's application, it'll be the 10th indication for tislelizumab in China, which speaks to its versatility as a cancer medicine as well as its money-making potential.

  • Zacks

    AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?

    AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.